Description
The ongoing GM-CSF trial represents a novel immunomodulatory approach, but optimal sequencing, combination, or stratification of such immune-based therapies with cholinesterase inhibitors or anti-amyloid antibodies remains unexplored and represents a critical therapeutic development question.